Rezolute(NASDAQ) RZLT

Rezolute develops medicines for rare metabolic diseases that cause dangerous low blood sugar. Its main drugs aim to help children with genetic disorders and adults with diabetes-related eye problems. These treatments target patients who have few other options for managing their conditions.

What’s in the Rezolute Medicine Cabinet?

• RZ358 (ersodetug): Antibody therapy for all forms of hyperinsulinism, a rare disorder causing low blood sugar; no revenue yet.
• RZ402: Oral drug for diabetic macular edema, a complication of diabetes that affects vision; no revenue yet.
• Expanded Access Program: Provides RZ358 to patients with severe hyperinsulinism who cannot use other treatments; no revenue yet.

Rezolute’s Growth Spurt: The Timeline Edition

• Launched Phase 3 trial for RZ358 in congenital hyperinsulinism in 2024.
• Planned to start registrational Phase 3 trial for RZ358 in tumor-induced hyperinsulinism in mid-2025.
• Secured licensing deals with XOMA and ActiveSite for key drug rights.
• Raised $62.6M in 2024 and $96.9M in 2025 through equity offerings.
• Expanded operations with new facility leases in Redwood City, CA, and Bend, OR.

Why Rezolute Isn’t Just Another Biotech

Rezolute focuses on rare diseases with few treatment options, using targeted therapies. Its drugs have received special regulatory designations to speed up development. The company’s expanded access program shows real-world demand for its lead therapy.

Five Things You Need to Know

• No revenue reported for QQ1 2024, QQ1 2025, or QQ1 2026.
• Operating loss was $20M in QQ1 2026, up 17% from prior year.
• Net loss was $18M in QQ1 2026, up 18% from prior year.
• R&D expenses rose 23% year-over-year to $15.3M for three months ended March 2025.

Bottom Line

Rezolute is a clinical-stage biotech focused on rare metabolic diseases. Its pipeline and funding reflect a strategy of targeting high-need, underserved patient groups.